Almirall and absci expand ai drug creation collaboration adding a second dermatology target

Barcelona, spain and vancouver, wash., aug. 07, 2025 (globe newswire) -- almirall (bme: alm), a global biopharmaceutical company focused on medical dermatology, and absci corporation (nasdaq: absi), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative ai, today announced the expansion of their ongoing ai drug discovery collaboration with almirall's selection of a second target aimed at dermatological indications.
ABSI Ratings Summary
ABSI Quant Ranking